Evaluation of methods to eliminate analytical interference in multiple myeloma patients with spurious hyperphosphatemia.

OBJECTIVE The acid/molybdate assay performed on the Beckman Coulter AU5821 could be subject to paraprotein interference, which potentially results in spurious hyperphosphatemia. We attempted to find a reliable solution to eliminate paraprotein interference in laboratory test results and discuss the causes of paraprotein interference. METHODS We observed 50 multiple myeloma patients with serum paraproteins. We used the trichloroacetic acid (TCA) deproteinizing method to confirm that paraproteins indeed interfered with phosphate detection in the serum acid/molybdate assay. Furthermore, we used the dry chemical method (Vitros 5.1 FS, Johnson) and deionized water (H2O), normal saline (NS), and healthy human serum as alternative diluents. We assessed the clinical acceptability of the 4 methods by evaluating a bias percentage (bias%) lower than 10% under the premise of TCA treatment as a serum phosphate reference method. RESULTS In total, comparing the results of the TCA treatment on the Beckman Coulter AU5821, 3/50 (6%) multiple myeloma patients exhibited phosphate pseudo-elevation (bias% >10%). Additionally, we found pseudo-hypophosphate only in immunoglobulin (Ig)G-kappa paraprotein samples, and all were above 50 g/L. The bias% between TCA and dry chemical method for the 3 patients was below 10%. The maximum acceptable dilutions for patient 22 were 8-fold H2O, 4-fold H2O , and 2-fold serum; those for patient 45 were 16-fold H2O, 16-fold H2O, and 2-fold serum. However, the bias% of patient 40 was beyond the acceptable range in all 3 dilution groups. CONCLUSION High concentrations of IgG kappa-type paraproteins are more likely to interfere with serum phosphorous detection. Both the TCA and dry chemical method can effectively eliminate paraprotein interference.

[1]  E. García-González,et al.  Analytical interference by monoclonal immunoglobulins on the direct bilirubin AU Beckman Coulter assay: the benefit of unsuspected diagnosis from spurious results , 2016, Clinical chemistry and laboratory medicine.

[2]  G. Pamuk,et al.  The rapid resolution of pseudohyperphosphatemia in an IGAκ multiple myeloma patient after therapy with a bortezomib-containing regimen: Report of the first case. , 2015, Journal of cancer research and therapeutics.

[3]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[4]  V. Roy Artifactual Laboratory Abnormalities in Patients with Paraproteinemia , 2009, Southern medical journal.

[5]  Junghye Choi,et al.  Pseudohyperphosphatemia in a Patient with Multiple Myeloma , 2007, Electrolyte & blood pressure : E & BP.

[6]  M. Gundogdu,et al.  Spuriously high phosphate level which is promptly resolved after plasmapheresis in a patient with multiple myeloma. , 2007, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[7]  V. Leblond,et al.  Make your diagnosis. Multiple myeloma-associated with spurious hyperphosphatemia. , 2007, Kidney international.

[8]  M. Umeda,et al.  Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma , 2006, Annals of Hematology.

[9]  J. Sarko,et al.  Bone and mineral metabolism. , 2005, Emergency medicine clinics of North America.

[10]  S. Oren,et al.  Hyperphosphatemia in multiple myeloma , 1994, Annals of Hematology.

[11]  Helen Smith,et al.  Spurious hyperphosphataemia caused by an IgA paraprotein: a topic revisited , 2004, Annals of clinical biochemistry.

[12]  P. Athanassiades,et al.  Pseudohyperphosphatemia in multiple myeloma , 1996, American journal of hematology.

[13]  Oswald Sonntag,et al.  Dry Chemistry: Analysis With Carrier-Bound Reagents , 1993 .

[14]  L. Lai,et al.  Pseudohyperphosphataemia in patients with multiple myeloma. , 1992, Journal of clinical pathology.